PT - JOURNAL ARTICLE AU - Schmidt, Insa M. AU - Mothi, Suraj Sarvode AU - Wilson, Parker C. AU - Palsson, Ragnar AU - Srivastava, Anand AU - Kibbelaar, Zoe A. AU - Zhuo, Min AU - Amodu, Afolarin AU - Stillman, Isaac E. AU - Rennke, Helmut G. AU - Humphreys, Benjamin D. AU - Waikar, Sushrut S. TI - Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease: Results from the Boston Kidney Biopsy Cohort AID - 10.1101/2021.04.14.21255472 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.14.21255472 4099 - http://medrxiv.org/content/early/2021/04/14/2021.04.14.21255472.short 4100 - http://medrxiv.org/content/early/2021/04/14/2021.04.14.21255472.full AB - Background Biomarkers for non-invasive assessment of histopathology and prognosis are needed in patients with kidney disease.Methods Using a proteomics assay, we measured a multi-marker panel of 225 circulating plasma proteins in a prospective cohort study of 549 individuals with biopsy-confirmed kidney diseases and semi-quantitative assessment of histopathology. We tested the associations of each biomarker with histopathologic lesions and the risks of kidney disease progression (defined as ≥40% decline in eGFR or ESKD) and death.Results After multivariable adjustment and correction for multiple testing, 46 proteins associated with different histopathologic lesions. The top performing markers positively associated with acute tubular injury and interstitial fibrosis and tubular atrophy were kidney injury molecule-1 (KIM-1) and V-set and immunoglobulin domain-containing protein 2 (VSIG2). 30 proteins were significantly associated with kidney disease progression and 35 with death. The top performing markers for kidney disease progression were placental growth factor (PGF; HR 5.4, 95% CI 3.4 to 8.7) and BMP and Activin Membrane Bound Inhibitor (BAMBI; HR 3.0, 95% CI 2.1 to 4.2); the top performing markers for death were TRAIL-receptor-2 (TRAIL-R2; HR 2.9, 95% CI 2.0 to 4.0) and CUB Domain Containing Protein-1 (CDCP1; HR 2.4, 95% CI 1.8, 3.3).Conclusion We identified several biomarkers associated with kidney disease histopathology and prognosis – many of which have not been reported previously and may represent important avenues for future research.Competing Interest StatementS.S.W. reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, GSK, Mass Medical International, Barron and Budd (vs. Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (aka Baim), and grants and personal fees from Allena Pharmaceuticals. A.S. reports personal fees from Horizon Pharma, PLC, AstraZeneca, CVS Caremark, and medicolegal consulting (Tate & Latham).Clinical TrialThis is a prospective, observational cohort study. The study was approved by the Partners Human Research Committee which is the Brigham and Womens Hospital Institutional Review Board.Funding StatementThis study was supported by National Institutes of Health (NIH) grant R01DK093574 (S.S.W.). I.M.S. is supported by the American Philosophical Society Daland Fellowship in Clinical Investigation. S.S.W. is also supported by NIH grants UH3DK114915, U01DK085660, U01DK104308, R01DK103784, and R21DK119751. A.S. is supported by NIH grant K23DK120811, NIDDK Kidney Precision Medicine Project Opportunity Pool grant under U2CDK114886, and core resources from the George M. O Brien Kidney Research Center at Northwestern University (NU-GoKIDNEY) P30DK114857. M.Z. is supported by a NIH NIDDK T32 award DK007199. This work was conducted with support from Harvard Catalyst. The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL1TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Partners Human Research Committee (the Brigham and Womens Hospital Institutional Review Board) approved the study protocol which is in accordance with the principles of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the Boston Kidney Biopsy Cohort are stored at the Brigham and Womens Hospital in Boston, MA. Data can be accessed upon request to the study PI Dr. Sushrut S. Waikar.